Codexis and Teva expand generic drugmaking deal; will Codexis revive IPO plans in 2010?

December 08, 2009 | Analyst Insight

Synthetic biology developer Codexis just announced that the world's largest generic drugmaker, Teva, is expanding the biocatalyst deal the companies signed in January. The new agreement covers three undisclosed pharmaceutical...

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978